• Histological or pathological confirmation of metastatic pancreas adenocarcinoma. Cytological or histological evidence of metastatic disease is required.

• Male or Female greater than or equal to 18 years of age.

• Eastern Cooperative Oncology Group (ECOG) performance score of 0-1.

• Life expectancy ≥ 3 months in the opinion of the Investigator.

• Measurable disease as per iRECIST criteria.

• Subjects must have tumors that express EGFR.

• Documented disease progression with first line FOLFIRINOX or NALIRIFOX therapy, during or within 3 months (+/- 15 days) after end of therapy.

• No more than one line of prior systemic therapy for metastatic PDAC allowed.

• Albumin level \> 3.0 g/dl

• Adequate hematological function.

• Adequate renal function.

• Adequate hepatic function.

• Adequate cardiac function with LVEF ≥ 50% at baseline.

• Reproductive criteria as follows:

• Female subjects who are of non-reproductive potential

• Female subjects of childbearing potential must have a negative serum pregnancy test within 14 days of the first dose.

• Female subjects must be willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last study drug administration.

• Male subjects must be willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last study drug administration.

• All study subjects must be willing to ensure that corresponding sexual partners practice these same methods of highly effective birth control for the same duration.

• The subject (or subject's legally authorized representative) has provided voluntary signed informed consent.

• According to the investigator's assessment, subject will be able to comply with the study protocol.